BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 32998139)

  • 1. TERT Promoter Mutation in Serum Cell-Free DNA Is a Diagnostic Marker of Primary Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease.
    Akuta N; Kawamura Y; Kobayashi M; Arase Y; Saitoh S; Fujiyama S; Sezaki H; Hosaka T; Kobayashi M; Suzuki Y; Suzuki F; Ikeda K; Kumada H
    Oncology; 2021; 99(2):114-123. PubMed ID: 32998139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of TERT promoter mutation in serum cell-free DNA using wild-type blocking PCR combined with Sanger sequencing in hepatocellular carcinoma.
    Akuta N; Suzuki F; Kobayashi M; Fujiyama S; Kawamura Y; Sezaki H; Hosaka T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Suzuki Y; Kumada H
    J Med Virol; 2020 Dec; 92(12):3604-3608. PubMed ID: 32100879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum TERT C228T is an important predictor of non-viral liver cancer with fatty liver disease.
    Akuta N; Kawamura Y; Suzuki F; Kobayashi M; Arase Y; Saitoh S; Muraishi N; Fujiyama S; Sezaki H; Hosaka T; Kobayashi M; Suzuki Y; Ikeda K; Kumada H
    Hepatol Int; 2022 Apr; 16(2):412-422. PubMed ID: 35306637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease.
    Beale G; Chattopadhyay D; Gray J; Stewart S; Hudson M; Day C; Trerotoli P; Giannelli G; Manas D; Reeves H
    BMC Cancer; 2008 Jul; 8():200. PubMed ID: 18638391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of combined circulating TERT promoter mutations and miR-122 expression for screening HBV-related hepatocellular carcinoma.
    Trung NT; Hoan NX; Trung PQ; Binh MT; Van Tong H; Toan NL; Bang MH; Song LH
    Sci Rep; 2020 May; 10(1):8181. PubMed ID: 32424223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of Cell-Free Human Telomerase Reverse Transcriptase Mutant DNA Quantification in Blood for Predicting Hepatocellular Carcinoma Treatment Efficacy.
    Muraoka M; Maekawa S; Katoh R; Komiyama Y; Nakakuki N; Takada H; Matsuda S; Suzuki Y; Sato M; Tatsumi A; Miura M; Amemiya F; Shindo H; Takano S; Fukasawa M; Yamauchi K; Yamaguchi T; Nakayama Y; Inoue T; Enomoto N
    Hepatol Commun; 2021 Nov; 5(11):1927-1938. PubMed ID: 34558819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic value of circulating cell-free DNA levels for hepatocellular carcinoma.
    Yan L; Chen Y; Zhou J; Zhao H; Zhang H; Wang G
    Int J Infect Dis; 2018 Feb; 67():92-97. PubMed ID: 29229500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TERT promoter mutations and chromosome 8p loss are characteristic of nonalcoholic fatty liver disease-related hepatocellular carcinoma.
    Ki Kim S; Ueda Y; Hatano E; Kakiuchi N; Takeda H; Goto T; Shimizu T; Yoshida K; Ikura Y; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Uemoto S; Chiba T; Ogawa S; Marusawa H
    Int J Cancer; 2016 Dec; 139(11):2512-8. PubMed ID: 27511114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosis and Resection Treatment of Triplet Hepatocellular Carcinomas with a non-B non-C Background in a Middle Aged Man over a Period of 6-years.
    Kajiwara A; Kinowaki K; Akuta N; Kasuya K; Muraishi N; Iritani S; Kawamura Y; Fujiyama S; Sezaki H; Hosaka T; Saitoh S; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Suzuki F; Kumada H; Suzuki Y
    Intern Med; 2020 Oct; 59(20):2511-2516. PubMed ID: 32581173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Utility of Protein Induced by Vitamin K Absence-II in Patients with Hepatocellular Carcinoma.
    Bhatti ABHH; Naz K; Abbas G; Khan NY; Zia HH; Ahmed IN
    Asian Pac J Cancer Prev; 2021 Jun; 22(6):1731-1736. PubMed ID: 34181327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.
    Cevik D; Yildiz G; Ozturk M
    World J Gastroenterol; 2015 Jan; 21(1):311-7. PubMed ID: 25574106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TERT promoter mutated circulating tumor DNA as a biomarker for prognosis in hepatocellular carcinoma.
    Oversoe SK; Clement MS; Pedersen MH; Weber B; Aagaard NK; Villadsen GE; Grønbæk H; Hamilton-Dutoit SJ; Sorensen BS; Kelsen J
    Scand J Gastroenterol; 2020 Dec; 55(12):1433-1440. PubMed ID: 33103505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic value of protein induced by vitamin K absence (PIVKAII) and hepatoma-specific band of serum gamma-glutamyl transferase (GGTII) as hepatocellular carcinoma markers complementary to alpha-fetoprotein.
    Cui R; He J; Zhang F; Wang B; Ding H; Shen H; Li Y; Chen X
    Br J Cancer; 2003 Jun; 88(12):1878-82. PubMed ID: 12799630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human Telomerase Reverse Transcriptase Gene Promoter Mutation in Serum of Patients with Hepatocellular Carcinoma.
    Ako S; Nouso K; Kinugasa H; Matsushita H; Terasawa H; Adachi T; Wada N; Takeuchi Y; Mandai M; Onishi H; Ikeda F; Shiraha H; Takaki A; Fujioka S; Mimura T; Okada H
    Oncology; 2020; 98(5):311-317. PubMed ID: 32135540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of the prognosis of advanced hepatocellular carcinoma by TERT promoter mutations in circulating tumor DNA.
    Hirai M; Kinugasa H; Nouso K; Yamamoto S; Terasawa H; Onishi Y; Oyama A; Adachi T; Wada N; Sakata M; Yasunaka T; Onishi H; Shiraha H; Takaki A; Okada H
    J Gastroenterol Hepatol; 2021 Apr; 36(4):1118-1125. PubMed ID: 32830343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined measurement of preoperative α-fetoprotein and des-γ-carboxy prothrombin predicts recurrence after curative resection in patients with hepatitis-B-related hepatocellular carcinoma.
    Chon YE; Choi GH; Lee MH; Kim SU; Kim DY; Ahn SH; Kim KS; Choi JS; Han KH; Chon CY; Park JY
    Int J Cancer; 2012 Nov; 131(10):2332-41. PubMed ID: 22362471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Favorable Impact of Serum TERT C228T for Prognosis after Surgical Resection for Liver Cancer.
    Akuta N; Kawamura Y; Fujiyama S; Sezaki H; Hosaka T; Saitoh S; Kobayashi M; Arase Y; Ikeda K; Suzuki Y; Kumada H; Suzuki F
    Oncology; 2023; 101(11):738-752. PubMed ID: 37651985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telomerase reverse transcriptase promoter mutations in hepatitis B virus-associated hepatocellular carcinoma.
    Yang X; Guo X; Chen Y; Chen G; Ma Y; Huang K; Zhang Y; Zhao Q; Winkler CA; An P; Lyu J
    Oncotarget; 2016 May; 7(19):27838-47. PubMed ID: 27056898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A simultaneous monitoring of Lens culinaris agglutinin A-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin as an early diagnosis of hepatocellular carcinoma in the follow-up of cirrhotic patients.
    Shimauchi Y; Tanaka M; Kuromatsu R; Ogata R; Tateishi Y; Itano S; Ono N; Yutani S; Nagamatsu H; Matsugaki S; Yamasaki S; Tanikawa K; Sata M
    Oncol Rep; 2000; 7(2):249-56. PubMed ID: 10671666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of tumor markers in the diagnosis of hepatocellular carcinoma, with special reference to the des-gamma-carboxy prothrombin.
    Grazi GL; Mazziotti A; Legnani C; Jovine E; Miniero R; Gallucci A; Palareti G; Gozzetti G
    Liver Transpl Surg; 1995 Jul; 1(4):249-55. PubMed ID: 9346575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.